Multi-omics blood atlas reveals unique features of immune and platelet responses to SARS-CoV-2 Omicron breakthrough infection

多组学血液图谱揭示了SARS-CoV-2 Omicron突破性感染的免疫和血小板反应的独特特征

阅读:1
作者:Hong Wang ,Cuicui Liu ,Xiaowei Xie ,Mingming Niu ,Yingrui Wang ,Xuelian Cheng ,Biao Zhang ,Dong Zhang ,Mengyao Liu ,Rui Sun ,Yezi Ma ,Shihui Ma ,Huijun Wang ,Guoqing Zhu ,Yang Lu ,Baiming Huang ,Pei Su ,Xiaoyuan Chen ,Jingjing Zhao ,Hongtao Wang ,Long Shen ,Lixia Fu ,Qianqian Huang ,Yang Yang ,He Wang ,Chunlong Wu ,Weigang Ge ,Chen Chen ,Qianyu Huo ,Qingping Wang ,Ying Wang ,Li Geng ,Yan Xie ,Yi Xie ,Lijun Liu ,Jianwei Qi ,Huaiyong Chen ,Junping Wu ,Erlie Jiang ,Wentao Jiang ,Ximo Wang ,Zhongyang Shen ,Tiannan Guo ,Jiaxi Zhou ,Ping Zhu ,Tao Cheng

Abstract

Although host responses to the ancestral SARS-CoV-2 strain are well described, those to the new Omicron variants are less resolved. We profiled the clinical phenomes, transcriptomes, proteomes, metabolomes, and immune repertoires of >1,000 blood cell or plasma specimens from SARS-CoV-2 Omicron patients. Using in-depth integrated multi-omics, we dissected the host response dynamics during multiple disease phases to reveal the molecular and cellular landscapes in the blood. Specifically, we detected enhanced interferon-mediated antiviral signatures of platelets in Omicron-infected patients, and platelets preferentially formed widespread aggregates with leukocytes to modulate immune cell functions. In addition, patients who were re-tested positive for viral RNA showed marked reductions in B cell receptor clones, antibody generation, and neutralizing capacity against Omicron. Finally, we developed a machine learning model that accurately predicted the probability of re-positivity in Omicron patients. Our study may inspire a paradigm shift in studying systemic diseases and emerging public health concerns.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。